| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Glutathione S-transferases (GST). JS-K is a nitric oxide donor prodrug that is metabolized by GST to release NO. The compound has antiproliferative activity and induces apoptosis in cancer cells.
|
|---|---|
| ln Vitro |
JS-K is a nitric oxide donor. It inhibits Jurkat T-cell acute lymphoblastic leukemia cell proliferation, induces apoptosis, and disrupts the cell cycle. The compound shows antiproliferative activity. Detailed in vitro activity against various cancer cell lines has been reported.
|
| ln Vivo |
JS-K has been evaluated in orthotopic rat glioma models assessed by MRI. The compound shows antiproliferative activity in vivo. JS-K has been studied for its effects on the blood-tumor barrier. Detailed in vivo efficacy in various tumor models has been reported.
|
| Enzyme Assay |
Nitric oxide release assay: JS-K is incubated with varying concentrations of glutathione S-transferases and a NO-sensitive fluorescent probe (e.g., DAF-FM) in assay buffer at 37°C. Fluorescence is measured over time. The rate and extent of NO release are quantified.
|
| Cell Assay |
Cell proliferation and apoptosis assay: Cancer cell lines (e.g., Jurkat T-cells) are treated with JS-K at varying concentrations for 24–72 hours. Cell viability is measured by MTT or CellTiter-Glo. Apoptosis is assessed by annexin V/PI staining and flow cytometry. Cell cycle distribution is analyzed by propidium iodide staining.
|
| Animal Protocol |
Orthotopic glioma model: Rats bearing orthotopic U87 gliomas are treated with JS-K. Tumor growth is monitored by MRI. The effects of JS-K on the blood-tumor barrier and tumor progression are assessed. Endpoints include tumor volume, survival, and histological analysis.
|
| ADME/Pharmacokinetics |
JS-K has a molecular weight of 384.30 g/mol and molecular formula C13H16N6O8. CAS number is 205432-12-8. Purity is ≥96%. The compound is a nitric oxide donor prodrug. Comprehensive PK parameters have been characterized.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data has been published. JS-K is for research use only. Standard laboratory safety practices should be followed when handling this compound. As an NO donor, potential effects on vascular function and blood pressure should be considered.
|
| References | |
| Additional Infomation |
JS-K is a nitric oxide donor prodrug that is metabolized by glutathione S-transferases to release NO. It has antiproliferative activity and inhibits Jurkat T-cell leukemia cell proliferation, induces apoptosis, and disrupts the cell cycle. JS-K has been evaluated in orthotopic glioma models. No clinical trials or approved上市 status have been reported.
|
| Molecular Formula |
C13H16N6O8
|
|---|---|
| Molecular Weight |
384.3
|
| Exact Mass |
384.103
|
| CAS # |
205432-12-8
|
| PubChem CID |
9572720
|
| Appearance |
White to yellow solid powder
|
| Density |
1.606g/cm3
|
| Boiling Point |
546.692ºC at 760 mmHg
|
| Flash Point |
284.429ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.656
|
| LogP |
2.893
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
27
|
| Complexity |
582
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCOC(=O)N1CCN(CC1)/[N+](=N/OC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-])/[O-]
|
| InChi Key |
DNJRNBYZLPKSHV-RGEXLXHISA-N
|
| InChi Code |
InChI=1S/C13H16N6O8/c1-2-26-13(20)15-5-7-16(8-6-15)19(25)14-27-12-4-3-10(17(21)22)9-11(12)18(23)24/h3-4,9H,2,5-8H2,1H3/b19-14-
|
| Chemical Name |
(Z)-(2,4-dinitrophenoxy)imino-(4-ethoxycarbonylpiperazin-1-yl)-oxidoazanium
|
| Synonyms |
JSK; JS K; JS-K
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6021 mL | 13.0107 mL | 26.0213 mL | |
| 5 mM | 0.5204 mL | 2.6021 mL | 5.2043 mL | |
| 10 mM | 0.2602 mL | 1.3011 mL | 2.6021 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
